Curi RMB Capital’s Tvardi Therapeutics TVRD Stock Holding History

Curi RMB Capital’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-15,111	Closed	-$277K	–	567
2024 Q4	$277K	Buy	+15,111	New	+$164K	0.01%	469

Other funds holding TVRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Curi RMB Capital's TVRD Position: Q1 2025 in Review

Curi RMB Capital sold out of Tvardi Therapeutics (TVRD) in Q1 2025, closing a stake of 15,111 shares — an estimated $277K sold.

Curi RMB Capital first reported a position in TVRD in Q4 2024 and held it in 1 quarter. The position peaked at $277K in Q4 2024. 33 funds tracked by Wall St. Rank hold TVRD as of Q1 2025.

Curi RMB Capital reported no remaining Tvardi Therapeutics position as of Q1 2025 after selling out during the quarter.
Curi RMB Capital sold 15,111 Tvardi Therapeutics shares in Q1 2025, an estimated $277K.
Curi RMB Capital first reported a position in Tvardi Therapeutics in Q4 2024 and held it in 1 quarter.
Curi RMB Capital's Tvardi Therapeutics position peaked at $277K in Q4 2024.
33 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2025.

Based on Curi RMB Capital's 13F filing for Q1 2025, filed 15 May 2025.